Detalhe da pesquisa
1.
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Ann Hematol
; 2024 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609726
2.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Cancer
; 129(7): 992-1004, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692409
3.
Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Support Care Cancer
; 30(2): 1521-1527, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34533630
4.
Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.
EMBO J
; 34(9): 1214-30, 2015 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25770584
5.
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
Haematologica
; 109(3): 988-993, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794811
6.
Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.
J Immunol
; 190(12): 6662-72, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23686482
7.
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.
Acta Haematol
; 129(2): 126-34, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23207803
8.
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?
Cancers (Basel)
; 16(1)2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201501
9.
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Ann Hematol
; 91(9): 1345-9, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22569854
10.
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Support Care Cancer
; 20(10): 2621-6, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22699304
11.
Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management.
Mediterr J Hematol Infect Dis
; 14(1): e2022073, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36425146
12.
Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network.
Cancers (Basel)
; 14(3)2022 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35159092
13.
Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center.
Acta Haematol
; 126(1): 1-7, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21411983
14.
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience.
Front Oncol
; 11: 740079, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34616684
15.
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Hematol Oncol
; 28(2): 89-92, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19728398
16.
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study.
Bone Marrow Transplant
; 55(11): 2114-2120, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346078
17.
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Clin Adv Hematol Oncol
; 10(4): 266-8, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22706491
18.
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.
Br J Haematol
; 152(1): 119-21, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21029071
19.
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
Haematologica
; 96(10): e41-2, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21972212
20.
Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.
Acta Oncol
; 49(3): 399-400, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20105089